Enobosarm, a selective androgen receptor modulator (SARM), is the Company’s lead product candidate and is being developed as a targeted treatment for two advanced breast cancer indications: estrogen receptor positive (ER+) and androgen receptor positive (AR+) breast cancer, and AR+ triple negative breast cancer (TNBC). Preliminary data from the first stage of both Phase 2 clinical trials are expected by the end of 2016
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.